Articles From: Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes to Santander Chairman Emilio Botín Dies


PARIS and MINNEAPOLIS, June 14, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT:SAN) (NYSE:SNY) and Medtronic, Inc. (NYSE:MDT) today announced that they have signed a memorandum of understanding to enter into a global strategic alliance in diabetes, aimed at improving patient experience and outcomes for people with diabetes around the world.
Sign-up for Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes investment picks
PARIS and TARRYTOWN, N.Y., July 9, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
Sign-up for Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis investment picks
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y. , Aug.
Sign-up for Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 investment picks
- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor - PARIS and TARRYTOWN, N.Y. , July 30, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator.
Sign-up for Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia investment picks
Sanofi Announces $2.5 Million Contribution to Dementia Research Canada NewsWire MONTREAL , Sept.
Sign-up for Sanofi Announces $2.5 Million Contribution to Dementia Research investment picks
2014/6/14
Sanofi Announces Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes Canada NewsWire - In EDITION JP I and II, investigational Toujeo ® demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs.
Sign-up for Sanofi Announces Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes investment picks
2014/9/9
Sanofi Canada launching YouTube Channel Canada NewsWire LAVAL, QC , Sept.
Sign-up for Sanofi Canada launching YouTube Channel investment picks
2014/8/20
By Inti Landauro PARIS--The U.S. Food and Drug Administration has given its approval to Sanofi SA's (SAN.FR) Cerdelga capsule for Gaucher disease, the French pharmaceutical company said.
Sign-up for Sanofi Gets U.S. FDA Approval for Gaucher Disease Treatment investment picks
2014/7/31
PARIS , July 31, 2014 /PRNewswire/ -- Sanofi, a global and diversified healthcare leader, reports results for the first half of 2014.
Sign-up for Sanofi H1 2014 Results - Interview with Chris Viehbacher investment picks
2014/8/12
Generics Division of Sanofi, Winthrop US, to Market the Drug BRIDGEWATER, N.J. , Aug.
Sign-up for Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection) investment picks
2014/8/13
- Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older - LYON, France , Aug.
Sign-up for Sanofi Pasteur Announces Publication of Positive Data for Fluzone® High-Dose Vaccine in The New England Journal of Medicine investment picks
- Largest U.S. influenza vaccine supplier, providing broad product portfolio, will distribute at least 65 million doses to help protect people across multiple age groups against the virus this season - SWIFTWATER, Pa.
Sign-up for Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States investment picks
2014/6/14
Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) Toujeo ® is the intended trade name for insulin glargine [rDNA origin] injection, 300 U/mL; formerly abbreviated as "U300". U300 is not currently approved or licensed anywhere in the world.
Sign-up for Sanofi Reports Positive Phase 3 Results for Toujeo(R) investment picks
2014/6/14
- Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time compared with Lantus® - - All studies in the phase 3 "EDITION" clinical trial program, including a study with type 1 patients, met their primary endpoint - - Toujeo dossier accepted by the EMA - PARIS , June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that, in a pooled analysis, investigational therapy Toujeo ® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia) at any time of day, including night-time events, compared with Lantus ® (insulin glargine [rDNA origin] injection, 100 U/mL). The pooled analysis comprised data from three differing type 2 patient populations.
Sign-up for Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) investment picks
2014/9/3
PARIS--French drug company Sanofi SA said Wednesday its candidate for a dengue vaccine was effective in 60.8% of cases in a Phase 3 study in Latin America.
Sign-up for Sanofi Trial Vaccine Effective Against Dengue investment picks
2014/9/3
By William Horobin PARIS--French drug company Sanofi SA said Wednesday its candidate for a dengue vaccine was effective in 60.8% of cases in a Phase 3 study in Latin America.
Sign-up for Sanofi Trial Vaccine Effective Against Dengue, Study Finds investment picks
NEW YORK (MarketWatch) -- Sanofi (SNY)(fr:san) and MannKind Corp.
Sign-up for Sanofi, MannKind to commercialize Afrezza insulin therapy investment picks
PARIS , July 31, 2014 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2014 Change (reported) Change (CER) Net sales €8,075m +0.9% +6.4% Business net income (1) €1,537m +3.9% +13.0% Business EPS (2) €1.17 +4.5% +13.4% In order to facilitate an understanding of our operational performance, Sanofi comments on the business net income statement.
Sign-up for Sanofi: Solid Sales and Business EPS Growth at CER investment picks
2014/6/14
Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine Canada NewsWire PARIS , June 14, 2014 /CNW/ - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia ® (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus ® (insulin glargine). Lowering of post-prandial glucose was measured as change from baseline in incremental area under the glucose curve for 4 hours after a standardized solid breakfast, at week 8.
Sign-up for Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine investment picks
2014/6/14
PARIS , June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia ® (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus ® (insulin glargine). Lowering of post-prandial glucose was measured as change from baseline in incremental area under the glucose curve for 4 hours after a standardized solid breakfast, at week 8.
Sign-up for Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering than Liraglutide when Both were Added to Insulin Glargine investment picks
2014/7/16
The revolutionary new device continues to gain traction in the Clinical Marketplace with new agreement to supply Novation, which operates 40 percent of the staffed beds in the United States! SAN DIEGO , July 16, 2014 /PRNewswire/ -- Sanomedics, Inc. (OTCQB: SIMH); Sanomedics, a medical technology holding company that focuses on providing game changing products, services and ideas, announced today that their Thermomedics subsidiary recently strengthened its penetration of the Professional Healthcare vital signs business with the signing of a long-term agreement with Novation , a world-renowned provider of healthcare supply chain expertise and contracting.
Sign-up for Sanomedics International Holdings, Inc. Subsidiary Thermomedics' Caregiver® Thermometer with TouchFree™ Technology Inks 3-YR pact with Novation. investment picks
2014/7/15
Restructuring of Santa Fe Debts With Senior Secured Creditors; New Chairman, Management and Board Appointments and; Plan to re-develop summit mine to production; Joint conference call on Wednesday, July 16 at 9 am PDT (12 pm EDT) ALBUQUERQUE, N.M. and VANCOUVER, British Columbia , July 15, 2014 /PRNewswire/ -- Santa Fe Gold Corporation (" Santa Fe ", OTCQB: SFEG) and Canarc Resource Corp.
Sign-up for Santa Fe Gold and Canarc Resource Announce Strategic Share Exchange; Commitment for $22 Million Gold Bond Financing investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0957697001&sourceType=1 http://www.ccnmatthews.com/logos/20050705-canarc.gif ALBUQUERQUE, NEW MEXICO and VANCOUVER, BRITISH COLUMBIA --
Sign-up for Santa Fe Gold and Canarc Resource Announce Strategic Share Exchange; Commitment for $22 Million Gold Bond Financing; Restructuring of Santa Fe Debts With Senior Secured Creditors investment picks
VANCOUVER, Canada , July 28, 2014 /PRNewswire/ -- Santa Fe Gold Corporation (" Santa Fe ") (OTCQB: SFEG) is pleased to announce an updated resource estimate for the Summit Mine, located in New Mexico, USA .
Sign-up for Santa Fe Gold Announces Updated Resource Estimate for the Summit Mine investment picks
ALBUQUERQUE, N.M. , June 18, 2014 /PRNewswire/ -- Santa Fe Gold Corporation (OTCQB: SFEG) (OTCBB: SFEG) today announced it has reached agreement with Columbus Exploration Corporation (CLX-TSX-V) to extend the term of the Mogollon option until November 21, 2014 .
Sign-up for Santa Fe Gold Extends Mogollon Option investment picks
ALBUQUERQUE, N.M., June 27, 2014 /PRNewswire/ -- Santa Fe Gold Corporation (OTCQB: SFEG) today announced its Board of Directors voted to terminate Pierce Carson's employment as President and CEO for cause, effective immediately.
Sign-up for Santa Fe Gold Terminates Pierce Carson as President & CEO; Names Jakes Jordaan as Interim CEO investment picks
GREENVILLE, S.C., Aug.
Sign-up for Santa Fe Imaging Deploys eRAD RIS investment picks
2014/8/28
Parents Invited to Share Child's Outstanding Academic Accomplishments for Chance to Win Spot in Santander/Revolution "Soccer Scholars" Clinic BOSTON , Aug.
Sign-up for Santander And New England Revolution Encourage Parents To Share Their Child's Academic Achievements For Chance To Play With The Pros investment picks
2014/9/10
MADRID-- Emilio Botín, chairman of Banco Santander SA and widely regarded as one of the most powerful people in Spain over the past three decades, has died aged 79, the Spanish bank said Wednesday.
Sign-up for Santander Chairman Emilio Botín Dies investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes to Santander Chairman Emilio Botín Dies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices